Symtuza

(cobicistat / darunavir / emtricitabine / tenofovir alafenamide)
Check Coverage Restrictions
Or select your Insurance from the list below:

Dosage & Administration

Testing: Prior to or when initiating SYMTUZA, test patients for HBV infection.

Prior to or when initiating SYMTUZA, and during treatment with SYMTUZA, on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus. ( 2.1)

Recommended dosage: One tablet taken once daily with food in adults and pediatric patients, weighing at least 40 kg. ( 2.2)

Renal Impairment:SYMTUZA is not recommended in patients with estimated creatinine clearance below 30 mL/min. ( 2.3)

Hepatic Impairment: SYMTUZA is not recommended in patients with severe hepatic impairment. ( 2.4)

Symtuza Prescribing Information

Symtuza Prior Authorization Resources

Most recent state uniform prior authorization forms

Benefits investigation

Symtuza PubMed™ News

    Symtuza Patient Education

    Patient toolkit